Literature DB >> 29967817

Residual Curarization and Postoperative Respiratory Complications Following Laparoscopic Sleeve Gastrectomy. The Effect of Reversal Agents: Sugammadex vs. Neostigmine.

Tiberiu Ezri1,2, Shmuel Evron1,2, Irina Petrov1, Pinhas Schachter3, Yitzhak Berlovitz4, Mordechai Shimonov3.   

Abstract

BACKGROUND: Incomplete muscle relaxant reversal or re-curarization may be associated with postoperative respiratory complications. In this retrospective study we compared the incidence of postoperative residual curarization and respiratory complications in association with the type of muscle relaxant reversal agent, sugammadex or neostigmine, in patients undergoing laparoscopic sleeve gastrectomy.
MATERIAL AND METHODS: We reviewed the charts of all patients (179) undergoing laparoscopic sleeve gastrectomy from July 2012 to July 2013 at Wolfson Medical Center. Sugammadex 1.5-2 mg/kg (112 patients) or neostigmine 2.5 mg (67 patients) were used as reversal agents. Results were compared by the type of reversal agent employed. Compared parameters included demographic and anaesthetic data, residual curarization, oxyhemoglobin saturation (SpO2) in the recovery room (PACU), episodes of SpO2 lower than 90% in PACU, unexpected intensive care (ICU) admissions, incidence of atelectasis and pneumonia, re-intubation and duration of hospitalization.
RESULTS: Obstructive sleep apnea syndrome (OSAS) was more frequent in the sugammadex group (19% vs. 8%; p = 0.026). Total intravenous anesthesia (TIVA) was more frequently associated with sugammadex (33% vs. 16%; p = 0.007). There were no differences in postoperative residual curarization, SpO2 < 90% episodes, reintubation, ICU admissions, pulmonary complications and duration of hospitalization.
CONCLUSION: With the inherent limitations of a retrospective study, the use of sugammadex following laparoscopic sleeve gastrectomy showed no advantage over neostigmine in terms of residual curarization and respiratory complications.

Entities:  

Keywords:  muscle relaxants; neostigmine; respiratory complications; reversal; sugammadex

Year:  2015        PMID: 29967817      PMCID: PMC5953289          DOI: 10.1515/jccm-2015-0009

Source DB:  PubMed          Journal:  J Crit Care Med (Targu Mures)        ISSN: 2393-1817


  15 in total

1.  Postoperative residual block after intermediate-acting neuromuscular blocking drugs.

Authors:  A H Hayes; R K Mirakhur; D S Breslin; J E Reid; K C McCourt
Journal:  Anaesthesia       Date:  2001-04       Impact factor: 6.955

2.  The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients.

Authors:  Yigal Leykin; Tommaso Pellis; Mariella Lucca; Giacomina Lomangino; Bernardo Marzano; Antonino Gullo
Journal:  Anesth Analg       Date:  2004-10       Impact factor: 5.108

Review 3.  Residual paralysis after emergence from anesthesia.

Authors:  Benoît Plaud; Bertrand Debaene; François Donati; Jean Marty
Journal:  Anesthesiology       Date:  2010-04       Impact factor: 7.892

4.  Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit.

Authors:  Glenn S Murphy; Joseph W Szokol; Jesse H Marymont; Steven B Greenberg; Michael J Avram; Jeffery S Vender
Journal:  Anesth Analg       Date:  2008-07       Impact factor: 5.108

5.  Intraoperative acceleromyography monitoring reduces symptoms of muscle weakness and improves quality of recovery in the early postoperative period.

Authors:  Glenn S Murphy; Joseph W Szokol; Michael J Avram; Steven B Greenberg; Jesse H Marymont; Jeffery S Vender; Jayla Gray; Elizabeth Landry; Dhanesh K Gupta
Journal:  Anesthesiology       Date:  2011-11       Impact factor: 7.892

6.  Complications occurring in the postanesthesia care unit: a survey.

Authors:  R Hines; P G Barash; G Watrous; T O'Connor
Journal:  Anesth Analg       Date:  1992-04       Impact factor: 5.108

7.  Impact of anesthesia management characteristics on severe morbidity and mortality.

Authors:  M Sesmu Arbous; Anneke E E Meursing; Jack W van Kleef; Jaap J de Lange; Huub H A J M Spoormans; Paul Touw; Frans M Werner; Diederick E Grobbee
Journal:  Anesthesiology       Date:  2005-02       Impact factor: 7.892

8.  Ideal versus corrected body weight for dosage of sugammadex in morbidly obese patients.

Authors:  P Van Lancker; B Dillemans; T Bogaert; J P Mulier; M De Kock; M Haspeslagh
Journal:  Anaesthesia       Date:  2011-06-21       Impact factor: 6.955

9.  Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent.

Authors:  Koen Suy; Karl Morias; Guy Cammu; Pol Hans; Wilbert G F van Duijnhoven; Marten Heeringa; Ignace Demeyer
Journal:  Anesthesiology       Date:  2007-02       Impact factor: 7.892

10.  Critical respiratory events in the postanesthesia care unit. Patient, surgical, and anesthetic factors.

Authors:  D K Rose; M M Cohen; D F Wigglesworth; D P DeBoer
Journal:  Anesthesiology       Date:  1994-08       Impact factor: 7.892

View more
  3 in total

1.  Prolonged neuromuscular blockade by non-depolarizing neuromuscular blocking agents.

Authors:  Michiko Higashi; Takahiro Tamura; Yushi U Adachi
Journal:  JA Clin Rep       Date:  2019-05-19

2.  Response to Higashi et al.

Authors:  Kuniaki Moriwaki; Kenji Kayashima
Journal:  JA Clin Rep       Date:  2019-08-13

3.  Analgesic and Anesthetic Efficacy of Rocuronium/Sugammadex in Otorhinolaryngologic Surgery: A Propensity Score-Matched Analysis.

Authors:  En-Bo Wu; Chao-Ting Hung; Sheng-Dean Luo; Shao-Chun Wu; Tsung-Yang Lee; Jo-Chi Chin; Peng-Neng Tsai; Johnson Chia-Shen Yang
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.